Get the Stockscreener App
2.545
3.58%
-0.105
After Hours:
2.58
0.035
+1.38%
Omniab Inc stock is traded at $2.545, with a volume of 742.53K.
It is down -3.58% in the last 24 hours and up +75.00% over the past month.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
See More
Previous Close:
$2.65
Open:
$2.67
24h Volume:
742.53K
Relative Volume:
1.25
Market Cap:
$368.96M
Revenue:
$18.67M
Net Income/Loss:
$-64.78M
P/E Ratio:
-4.4115
EPS:
-0.5769
Net Cash Flow:
$-37.02M
1W Performance:
+7.81%
1M Performance:
+75.00%
6M Performance:
+37.37%
1Y Performance:
+85.14%
1-Day Range:
$2.47
$2.68
1-Week Range:
$2.40
$2.73
52-Week Range:
$1.22
$2.73
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
2.545 | 384.18M | 18.67M | -64.78M | -37.02M | -0.5769 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
OmniAb Stock Is Back Near Its High — Why OABI’s Next Few Days Matter - Bez Kabli
OmniAb, Inc. Hits New 52-Week High at USD 2.73 - Markets Mojo
OmniAb Inc. (OABI) Shares Edge Higher as Key Support HoldsSocial Investment Platform - Newser
OmniAb Inc. (OABI) Rallies 3.9% as Stock Tests Key Resistance LevelsExpert Entry Points - Newser
Is OmniAb Positioned To Be A Long-Term Biotech Winner? - RTTNews
OmniAb, Inc. Common Stock OABI ) Stock Price Today & Analysis - Gotrade
OmniAb unveils OmniUltra in vivo platform at TIDES USA event - Traders Union
OmniAb, Inc. (OABI) reports Q1 loss, tops revenue estimates - MSN
We're Hopeful That OmniAb (NASDAQ:OABI) Will Use Its Cash Wisely - Moomoo
TradingKey - TradingKey
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook - MSN
OmniAb, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:OABI) 2026-05-11 - Seeking Alpha
Number of shareholders of OmniAb, Inc. – NASDAQ:OABIW - TradingView
OmniAb (NASDAQ:OABI) Issues Earnings Results - MarketBeat
OmniAb Reports Strong Revenue Growth Driven by Clinical Partner Progress - HarianBasis.co
OmniAb, Inc. (NASDAQ:OABI) Q1 2026 Earnings Call Transcript - Insider Monkey
OmniAb (OABI) FY 2025 Loss Of US$64.8m Keeps Profitability Narrative Under Pressure - Sahm
OmniAb Earnings Call Highlights Surge In Milestones - TipRanks
OmniAb’s Q1 2026 Revenue Rises to $25.3 Million, Net Loss Decreases - geneonline.com
OmniAb unveils in vivo platform for human antibody and peptide discovery at 2026 PEGS Summit - Traders Union
OmniAb (OABI) Q1 2026 Earnings Transcript - AOL.com
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Announces Target Price $7 - Moomoo
OmniAb, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
OmniAb Q1 2026 slides: revenue surges 243%, guidance raised By Investing.com - Investing.com Australia
OmniAb Q1 Earnings Call Highlights - MarketBeat
TD Cowen Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $3 - Moomoo
H.C. Wainwright Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
The organic vs inorganic growth story at OmniAb (OABI) | Q1 2026: EPS Beats ForecastsAI Stock Signals - newser.com
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights - BioSpace
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates - Yahoo! Finance Canada
Earnings call transcript: OmniAb Q1 2026 sees revenue surge, stock climbs - Investing.com
OmniAb Q1 2026 slides: revenue surges 243%, guidance raised - Investing.com India
Earnings call transcript: OmniAb Q1 2026 sees revenue surge, stock climbs By Investing.com - Investing.com South Africa
OmniAb (NASDAQ:OABI) Surges on Q1 Beat and Raised 2026 Guidance - ChartMill
OmniAb : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
OmniAb : 1Q26 Earnings Presentation - marketscreener.com
OmniAb to Participate in Two Investor Conferences in November - Quantisnow
OmniAb, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
OmniAb has 107 partners and 409 programs — and just raised guidance - Stock Titan
OABI: Revenue surged and losses narrowed in Q1 2026, prompting an upward revision to full-year guidance - TradingView
OmniAb Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omniab Inc Stock (OABI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Option Exercise |
0.00 |
36,459 |
0 |
4,439,736 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Sale |
1.49 |
19,244 |
28,674 |
4,420,492 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):